Solesence AI Stock Analysis
Want to see SLSN full AI Analyst Report?
Solesence (SLSN) AI Stock Analysis
Solesence
(NASDAQ:SLSN)
Solesence's solid overall score is driven primarily by an exceptional operational turnaround and a record-breaking earnings report, highlighted by surging gross margins and strong free cash flow generation. However, the score is tempered by a stretched valuation profile and heavily overbought technical indicators, suggesting the stock's recent price appreciation may already price in much of the good news. Mixed corporate events, including a recent minimum bid price notice, also warrant moderate investor caution despite improving fundamentals.
Solesence (SLSN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $113.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 357.40K
- Price to Earnings (P/E)
- 38.5
- Beta (1Y)
- 2.41
- Revenue Growth
- -1.95%
- EPS Growth
- 122.62%
- Country
- US
- Employees
- 115
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Solesence Business Overview & Revenue Model
Company Description
Solesence, Inc., formerly known as Nanophase Technologies Corporation, specializes in the development and production of clean-label, inclusive, and mineral-based skincare and cosmetic products. The company collaborates with a diverse range of partner...
How the Company Makes Money
Solesence makes money primarily by selling specialty ingredient products and formulation solutions to customers (e.g., consumer brands and contract manufacturers) that incorporate these materials into finished goods such as sunscreens and other perso...
Solesence Earnings Call Summary
The call was predominantly positive, supported by record third-quarter revenue and net income, substantial gross-margin expansion, improved manufacturing efficiency, lower labor and indirect costs, and confidence in continued momentum into the fourth quarter and 2027. The main negatives were the reduction of full-year EBITDA margin expectations below the previously communicated double-digit target, remaining operational improvement needs, customer concentration, and the timing of expected commercial growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects shipped and on-hand orders to reach at least $65 million by year end and 2026 to be a third consecutive year of record revenue growth and profit growth, while maintaining a 30% gross profit floor for the year, with the potential to exceed this level as we finish 2026 and move forward into 2027. Full-year EBITDA margins are expected to be slightly below the previously communicated double-digit target, and the company is no longer guiding towards double-digit growth this year, saying it expects it to be a little bit less than that; fourth-quarter EBITDA margins are expected to remain well above first half levels. Looking ahead, Solésence believes it can achieve greater than 20% EBITDA, expects to grow in 2027, and thinks greater growth is in 2028 than it is in 2027, although that is not official guidance.
Solesence Financial Statement Overview
Summary
Financial performance reflects a compelling turnaround narrative. The company successfully stabilized revenue, restored its equity base, and engineered a massive reversal to generate positive free cash flow. However, moderate leverage and historical volatility in margins remain areas of caution.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
76Positive| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.94M | 62.06M | 52.35M | 37.30M | 37.32M | 29.48M |
| Gross Profit | 19.43M | 16.03M | 16.19M | 7.83M | 8.36M | 8.69M |
| EBITDA | 5.11M | 3.69M | 6.06M | -2.80M | -1.69M | 3.96M |
| Net Income | 2.91M | 1.79M | 4.24M | -4.39M | -2.62M | 2.32M |
Balance Sheet | ||||||
| Total Assets | 44.44M | 50.05M | 50.00M | 32.88M | 33.56M | 28.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.27M | 1.29M | 1.41M | 1.72M | 2.19M | 657.00K |
| Total Debt | 9.14M | 24.32M | 15.30M | 21.26M | 18.11M | 14.75M |
| Total Liabilities | 27.69M | 32.42M | 35.06M | 30.98M | 27.91M | 20.93M |
| Stockholders Equity | 16.75M | 17.63M | 14.95M | 1.90M | 5.65M | 7.46M |
Cash Flow | ||||||
| Free Cash Flow | 7.30M | -10.71M | -2.59M | -3.06M | -4.47M | 447.00K |
| Operating Cash Flow | 10.25M | -8.57M | 1.97M | -2.01M | -1.65M | 2.32M |
| Investing Cash Flow | -1.99M | -2.14M | -4.56M | -1.05M | -2.82M | -1.87M |
| Financing Cash Flow | -7.42M | 10.59M | 2.27M | 2.59M | 6.00M | -747.00K |
Solesence Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLSN, the sentiment is Positive. The current price of 1.60 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.87, and above the 200-day MA of 1.04, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 84.56 is Negative, neither overbought nor oversold. The STOCH value of 62.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLSN.
Solesence Risk Analysis
Solesence disclosed 27 risk factors in its most recent earnings report. Solesence reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksSolesence Peers Comparison
Overall Rating
SLSN70Outperform
HELE55Neutral
SKIN54Neutral
EPC51Neutral
NUS41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | $113.04M | 38.48 | 18.04% | ― | -1.95% | 122.62% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 55Neutral | $880.66M | -8.63 | -11.86% | ― | 0.52% | 84.94% | |
| 54Neutral | $98.46M | -5.32 | -32.09% | ― | -4.41% | -51.42% | |
| 51Neutral | $1.31B | -24.92 | -3.53% | 2.11% | -10.21% | -310.40% | |
| 41Neutral | $191.30M | -0.81 | -34.83% | 6.11% | -15.27% | -318.35% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SLSN | Solesence, Inc | 1.60 | -0.27 | -14.44% | |
| HELE | Helen Of Troy | 37.65 | 19.95 | 112.71% | |
| NUS | Nu Skin Enterprises | 3.93 | -5.27 | -57.27% | |
| EPC | Edgewell Personal Care Co | 28.38 | 11.98 | 73.08% | |
| SKIN | Beauty Health Company | 15.05 | -11.15 | -42.56% |
Solesence Corporate Events
Solesence Extends Maturity of Affiliate Loan Agreements
PositiveOn September 30, 2026, Solésence, Inc. amended three existing loan agreements with Strandler, LLC and Beachcorp, LLC, both affiliates of controlling shareholder Bradford T. Whitmore. The fourth amendments to its term, amended and restated, and revolv...
Solesence Receives Nasdaq Non-Compliance Minimum Bid Notice
NegativeOn September 29, 2026, Solésence, Inc. disclosed that it had received written notice from Nasdaq that its common stock had closed below $1.00 per share for 30 consecutive trading days, putting the company out of compliance with Nasdaq’s minimum bid p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
